285 related articles for article (PubMed ID: 34440698)
1. A Nut for Every Bolt: Subunit-Selective Inhibitors of the Immunoproteasome and Their Therapeutic Potential.
Huber EM; Groll M
Cells; 2021 Jul; 10(8):. PubMed ID: 34440698
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors.
Kirk CJ; Muchamuel T; Wang J; Fan RA
Cells; 2021 Dec; 11(1):. PubMed ID: 35011570
[TBL] [Abstract][Full Text] [Related]
3. Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome.
Fang Y; Johnson H; Anderl JL; Muchamuel T; McMinn D; Morisseau C; Hammock BD; Kirk C; Wang J
Drug Metab Dispos; 2021 Sep; 49(9):810-821. PubMed ID: 34234005
[TBL] [Abstract][Full Text] [Related]
4. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
5. A patent review of immunoproteasome inhibitors.
Ogorevc E; Schiffrer ES; Sosič I; Gobec S
Expert Opin Ther Pat; 2018 Jul; 28(7):517-540. PubMed ID: 29865878
[TBL] [Abstract][Full Text] [Related]
6. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
7. The immunoproteasome: a novel drug target for autoimmune diseases.
Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
[TBL] [Abstract][Full Text] [Related]
8. Immunoproteasome-selective inhibitors: the future of autoimmune diseases?
Zhang C; Zhu H; Shao J; He R; Xi J; Zhuang R; Zhang J
Future Med Chem; 2020 Feb; 12(4):269-272. PubMed ID: 31983229
[No Abstract] [Full Text] [Related]
9. Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases.
Ettari R; Previti S; Bitto A; Grasso S; Zappalà M
Curr Med Chem; 2016; 23(12):1217-38. PubMed ID: 26965184
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the immunoproteasome: current status and future directions.
Miller Z; Ao L; Kim KB; Lee W
Curr Pharm Des; 2013; 19(22):4140-51. PubMed ID: 23181576
[TBL] [Abstract][Full Text] [Related]
11. The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.
Zerfas BL; Maresh ME; Trader DJ
J Med Chem; 2020 Mar; 63(5):1841-1858. PubMed ID: 31670954
[TBL] [Abstract][Full Text] [Related]
12. Immunoproteasome Function in Normal and Malignant Hematopoiesis.
Tubío-Santamaría N; Ebstein F; Heidel FH; Krüger E
Cells; 2021 Jun; 10(7):. PubMed ID: 34206607
[TBL] [Abstract][Full Text] [Related]
13. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism.
Wang J; Fang Y; Fan RA; Kirk CJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769030
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
15. On the role of the immunoproteasome in transplant rejection.
Basler M; Li J; Groettrup M
Immunogenetics; 2019 Mar; 71(3):263-271. PubMed ID: 30220008
[TBL] [Abstract][Full Text] [Related]
16. Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Cao Y; Zhu H; He R; Kong L; Shao J; Zhuang R; Xi J; Zhang J
Drug Des Devel Ther; 2020; 14():4327-4342. PubMed ID: 33116419
[TBL] [Abstract][Full Text] [Related]
17. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.
Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M
Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189
[TBL] [Abstract][Full Text] [Related]
18. Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.
Kollár L; Gobec M; Proj M; Smrdel L; Knez D; Imre T; Gömöry Á; Petri L; Ábrányi-Balogh P; Csányi D; Ferenczy GG; Gobec S; Sosič I; Keserű GM
Cells; 2021 Dec; 10(12):. PubMed ID: 34943940
[TBL] [Abstract][Full Text] [Related]
19. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.
Basler M; Groettrup M
Genes Immun; 2020 Nov; 21(5):273-287. PubMed ID: 32839530
[TBL] [Abstract][Full Text] [Related]
20. Noncytotoxic Inhibition of the Immunoproteasome Regulates Human Immune Cells In Vitro and Suppresses Cutaneous Inflammation in the Mouse.
Ah Kioon MD; Pierides M; Pannellini T; Lin G; Nathan CF; Barrat FJ
J Immunol; 2021 Apr; 206(7):1631-1641. PubMed ID: 33674446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
